ATHENEX INC (NASDAQ:ATNX) is scheduled to post its quarterly earnings results before the market opens on Monday, August 14th.

ATHENEX INC (NASDAQ ATNX) opened at 14.41 on Monday. The firm’s market cap is $586.29 million. ATHENEX INC has a one year low of $11.21 and a one year high of $20.79. The stock has a 50 day moving average of $16.86 and a 200 day moving average of $16.86.

Separately, Deutsche Bank AG started coverage on shares of ATHENEX INC in a research report on Monday, July 10th. They set a “buy” rating and a $20.00 price objective for the company.

In other news, Director Song-Yi Zhang acquired 328,637 shares of the firm’s stock in a transaction dated Monday, June 19th. The stock was bought at an average cost of $11.00 per share, for a total transaction of $3,615,007.00. Following the completion of the transaction, the director now directly owns 4,000 shares in the company, valued at approximately $44,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Johnson Yiu Nam Lau acquired 25,200 shares of the firm’s stock in a transaction dated Monday, June 19th. The shares were purchased at an average price of $11.00 per share, with a total value of $277,200.00. Following the completion of the transaction, the chief executive officer now owns 2,722,722 shares of the company’s stock, valued at $29,949,942. The disclosure for this purchase can be found here.

ILLEGAL ACTIVITY NOTICE: “ATHENEX INC (NASDAQ:ATNX) Scheduled to Post Earnings on Monday” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://www.dailypolitical.com/2017/08/07/athenex-inc-nasdaqatnx-scheduled-to-post-earnings-on-monday.html.

About ATHENEX INC

Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.

Receive News & Ratings for ATHENEX INC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ATHENEX INC and related companies with MarketBeat.com's FREE daily email newsletter.